Yunnan Botanee Bio-Technology Group (300957.SZ) Restricted Shares Unlocked Industry Insiders: The Unlocking of Restricted Shares Does Not Equal Reducing Holdings

According to Wind data, Yunnan Botanee Bio-Technology Group (300957.SZ) recently announced that approximately 206 million restricted shares of the company will be unlocked on March 25, accounting for about 48.68% of the total share capital of the company. Industry professionals pointed out that the unlocking of restricted shares does not necessarily mean selling. According to the rules of original share reduction, original shareholders need to disclose information 15 days before the implementation of the reduction and are subject to strict proportion and time limits. In the current secondary market environment and stock price performance, major shareholders will consider their control rights, the company's long-term stable development, and maintaining the long-term value of the company's stock price, among other factors, and stand in unity with small and medium shareholders to jointly uphold the long-term value of the company's stock price. As indicated in a previous announcement, Mr. Guo Zhenyu, chairman of Yunnan Botanee Bio-Technology Group, the actual controlling shareholder of Yunnan Botanee Bio-Technology Group, submitted a proposal letter for repurchasing shares on August 23, 2023, expressing confidence in the company's future development and recognition of the company's value. The price range for repurchasing shares is not more than RMB 130 per share, with a total repurchase fund of 100 million to 200 million yuan, representing approximately 0.18% to 0.36% of the total share capital of the company. It is worth noting that in order to effectively protect the interests of shareholders, enhance investor confidence, and fully mobilize the enthusiasm of company employees, the company adjusted the repurchase plan on October 30, increasing the total repurchase fund to 200 million to 300 million yuan, with the adjusted repurchase quantity of approximately 1.54 million to 2.31 million shares, accounting for approximately 0.36% to 0.54% of the total share capital of the company. This upward adjustment of the repurchase plan not only provides important support for market confidence but also demonstrates the optimistic attitude of the company's management towards the prospects of the enterprise. Not only does the company's management continue to have a positive outlook, but in the past 30 days, the amount of northbound funds held by Yunnan Botanee Bio-Technology Group has increased by 4.2491 million shares, representing an increase of 1.96% in the proportion of circulating shares. With a significant increase in holdings in the current stage of the company's stock price, foreign funds also actively look forward to the long-term stable development trend and investment value of Yunnan Botanee Bio-Technology Group. According to Wind data, since its listing three years ago, the company has continued to distribute cash dividends annually, totaling 783.66 million yuan in cash dividends. Through cash dividends, investors are effectively able to share in the growth and development achievements of the company, continuously strengthening the sense of identification and satisfaction among a large number of investors. On March 1, Yunnan Botanee Bio-Technology Group held a theme event titled "Setting off Again Here" at the Shanghai Center, marking the first strategic upgrade of the brand "Wenona" since its establishment. Witnessed by a group of Chinese authoritative dermatologists, Wenona officially entered the 2.0 stage, transitioning from healing sensitive skin to a new era of healthy skin freedom. At the event, the chairman of the Yunnan Botanee Bio-Technology Group, Guo Zhenyu, also announced 8 major strategic investment directions for the brand, including basic research and clinical innovation, global layout of scientific research system, development of Chinese characteristic plant industry chain, global market competition, and other dimensions. Currently, in addition to the main brand "Wenona," Yunnan Botanee Bio-Technology Group has also developed a baby skincare brand "Wenona Baby," and has successively launched a high-efficiency anti-aging brand "AOXMED Aixi Man" and a professional anti-acne brand "Beifen." In addition, by the end of 2023, the company strategically acquired the Yuejiang Group, supplementing the mainstream beauty care brands Pomei and Za Jirui, continuously enriching the brand matrix to enhance the company's core competitiveness. With a diverse range of product types and price ranges, Yunnan Botanee Bio-Technology Group is expected to cover a wider consumer base, tapping into market demand to gain more market share and growth potential. Donghai Securities mentioned the downward channel dividend in the beauty care industry, with overall demand performance slowing down, leading to some degree of differentiation in the performance of domestic brands, with high-quality domestic brands showing a strong position. Influenced by factors such as the Japanese nuclear wastewater incident, changes in consumer consumption concepts, and the rise of Chinese style, domestic cosmetics have encountered opportunities and development space. Consumer awareness and demand for domestic products continue to increase, with domestic rankings gradually improving and domestic penetration expected to further increase. It is believed that under the mission of creating a healthy skin ecosystem in China, Wenona, already in the 2.0 era, will set a new benchmark for skin health ecology with visionary leadership, continuing to play a pioneering and leading role in the innovation of Chinese beauty.